FREMONT, Calif., Nov. 5 /PRNewswire-FirstCall/ -- WaferGen Biosystems, Inc. , a leading developer of state-of-the-art genetic analysis systems, today announced that Christopher Sears, Ph.D. has joined the company’s Scientific Advisory Board. His career has been focused on designing and commercializing novel molecular diagnostics for cancer detection and other applications, and on the development of computational biology systems for several biotechnology companies and academic institutions.
“I am looking forward to joining WaferGen’s Scientific Advisory Board as I believe the SmartChip technology offers significant untapped potential for a host of applications requiring improved genetic analysis,” said Christopher Sears, Ph.D. “My background lends itself to assisting WaferGen now as the company seeks to ramp up its collaborations and become the leading platform for gene expression work. I see multiple benefits offered by this technology and am pleased to be able to be a part of what I believe will be a true, next-generation advance in the medical field.”
About WaferGen
WaferGen Biosystems, Inc. is a leader in the development, manufacture and sale of state-of-the-art systems for genetic analysis for the life science and pharmaceutical industries. The company is actively developing its SmartChip(TM) product for the gene expression and genotyping markets. SmartChip is being developed as the first whole genome high throughput gene expression, real-time PCR platform. This innovative system, combined with next-generation chemistry and optimized assays being developed by WaferGen, promises to deliver significant speed and cost advantages to researchers in the gene expression and genotyping markets. Based on collaborations established with leading research institutions, WaferGen believes that the SmartChip Real-Time PCR System is positioned as the platform of choice for biomarker discovery and validation.
Forward-Looking Statements
This press release contains certain “forward-looking statements”. Such statements include statements relating to the expected benefits to the company of Dr. Sears’ appointment to the company’s Scientific Advisory Board, the expected benefits of the SmartChip technology to other applications, and other statements relating to future events or to the company’s future financial performance and are not historical facts, including statements which may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words.
CONTACT: Mona Chadha of WaferGen, +1-510-651-4450,
Mona.chadha@wafergen.com
Web site: http://www.wafergen.com/
